424 related articles for article (PubMed ID: 27060000)
1. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
[TBL] [Abstract][Full Text] [Related]
2. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
4. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
5. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes.
Garbe Y; Maletzki C; Linnebacher M
PLoS One; 2011; 6(11):e26517. PubMed ID: 22110587
[TBL] [Abstract][Full Text] [Related]
6. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
[TBL] [Abstract][Full Text] [Related]
7. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution.
Ballhausen A; Przybilla MJ; Jendrusch M; Haupt S; Pfaffendorf E; Seidler F; Witt J; Hernandez Sanchez A; Urban K; Draxlbauer M; Krausert S; Ahadova A; Kalteis MS; Pfuderer PL; Heid D; Stichel D; Gebert J; Bonsack M; Schott S; Bläker H; Seppälä T; Mecklin JP; Ten Broeke S; Nielsen M; Heuveline V; Krzykalla J; Benner A; Riemer AB; von Knebel Doeberitz M; Kloor M
Nat Commun; 2020 Sep; 11(1):4740. PubMed ID: 32958755
[TBL] [Abstract][Full Text] [Related]
8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
9. The Immune Biology of Microsatellite-Unstable Cancer.
Kloor M; von Knebel Doeberitz M
Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532
[TBL] [Abstract][Full Text] [Related]
10. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.
Linnebacher M; Gebert J; Rudy W; Woerner S; Yuan YP; Bork P; von Knebel Doeberitz M
Int J Cancer; 2001 Jul; 93(1):6-11. PubMed ID: 11391614
[TBL] [Abstract][Full Text] [Related]
11. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
12. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
[TBL] [Abstract][Full Text] [Related]
13. Immunological Features with DNA Microsatellite Alterations in Patients with Colorectal Cancer.
Raeker MO; Carethers JM
J Cancer Immunol (Wilmington); 2020; 2(3):116-127. PubMed ID: 33000102
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
15. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
[No Abstract] [Full Text] [Related]
16. Microsatellite instability in colorectal cancer.
De' Angelis GL; Bottarelli L; Azzoni C; De' Angelis N; Leandro G; Di Mario F; Gaiani F; Negri F
Acta Biomed; 2018 Dec; 89(9-S):97-101. PubMed ID: 30561401
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and molecular consequences of microsatellite instability in human cancers].
Hamelin R; Chalastanis A; Colas C; El Bchiri J; Mercier D; Schreurs AS; Simon V; Svrcek M; Zaanan A; Borie C; Buhard O; Capel E; Zouali H; Praz F; Muleris M; Fléjou JF; Duval A
Bull Cancer; 2008 Jan; 95(1):121-32. PubMed ID: 18230578
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability.
Ishikawa T; Fujita T; Suzuki Y; Okabe S; Yuasa Y; Iwai T; Kawakami Y
Cancer Res; 2003 Sep; 63(17):5564-72. PubMed ID: 14500396
[TBL] [Abstract][Full Text] [Related]
19. MONET: a database for prediction of neoantigens derived from microsatellite loci.
Deng N; Sinha KM; Vilar E
Front Immunol; 2024; 15():1394593. PubMed ID: 38835776
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]